Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 16 to 30 of 44 results for botulinum toxin type a

  1. Occipital nerve stimulation for intractable chronic migraine (IPG452)

    Evidence-based recommendations on occipital nerve stimulation for intractable chronic migraine. This involves using implanted electrodes to deliver electrical impulses to the occipital nerve to mask migraine pain.

    Interventional procedures guidance
    Published
    26 April 2013
    View recommendations

    Sections for IPG452

  2. Transcranial magnetic stimulation for treating and preventing migraine (IPG477)

    Evidence-based recommendations on transcranial magnetic stimulation for treating and preventing migraine. This involves placing a handheld device on the scalp to deliver magnetic pulses to the head.

    Interventional procedures guidance
    Published
    23 January 2014
    View recommendations

    Sections for IPG477

  3. Cerebral palsy in under 25s: assessment and management (NG62)

    This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.

    NICE guideline
    Published
    25 January 2017
    View recommendations

    Sections for NG62

  4. Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (IPG552)

    Evidence-based recommendations on transcutaneous stimulation of the cervical branch of the vagus nerve to treat cluster headache and migraine in adults. This involves using a small handheld device to stimulate a nerve in the neck.

    Interventional procedures guidance
    Published
    23 March 2016
    View recommendations

    Sections for IPG552

  5. Safety and efficacy of botulinum toxin:- What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with neurogenic lower urinary tract dysfunction?

    Question Safety and efficacy of botulinum toxin:- What is the safety and efficacy of botulinum...

    Research recommendation
    Published
    9 June 2015

  6. Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine (IPG740)

    Evidence-based recommendations on transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine in adults. This involves attaching a small device on the forehead to send small electrical currents to the nerves that bring sensation to the upper eyelids, forehead and scalp.

    Interventional procedures guidance
    Published
    26 October 2022
    View recommendations

    Sections for IPG740

  7. Mollii suit for spasticity (MIB100)

    NICE has a developed medtech innovation briefing on Mollii suit for spasticity .

    Medtech innovation briefing
    Published
    28 March 2017

  8. Functional electrical stimulation for drop foot of central neurological origin (IPG278)

    Evidence-based recommendations on functional electrical stimulation for drop foot of central neurological origin. This involves stimulating the peripheral nerves that supply the paralysed muscle using electrodes to restore muscular function.

    Interventional procedures guidance
    Published
    28 January 2009
    View recommendations

    Sections for IPG278

  9. Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]

    In development Reference number: GID-TAG499 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with primary cerebral conditions with lower urinary tract dysfunction?

    CG148/5 Question What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and...

    Research recommendation
    Published
    9 June 2015

  11. Motor neurone disease: assessment and management (NG42)

    This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.

    NICE guideline
    Last updated
    23 July 2019
    View recommendations

    Sections for NG42

  12. Further research should ideally be in the form of randomised controlled trials. Details of patient selection, the procedure and long-term outcomes should be reported.

    reported. Source guidance details Comes from guidance Botulinum toxin type A injections into the urethral sphincter for idiopathic...

    Research recommendation
    Published
    7 August 2023

  13. Atogepant for preventing migraine (TA973)

    Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.

    Technology appraisal guidance
    Published
    15 May 2024
    View recommendations

    Sections for TA973

  14. Lower urinary tract symptoms in men: management (CG97)

    This guideline covers managing lower urinary tract symptoms (LUTS) in men over 18. It aims to improve the quality of life for men with LUTS by recommending which assessments they should receive, and when conservative management, drug treatment and surgery can help.

    Clinical guideline
    Last updated
    3 June 2015
    View recommendations

    Sections for CG97

  15. Urinary incontinence in women (QS77)

    This quality standard covers managing urinary incontinence in women (aged 18 and over). It covers assessment, care and treatment options. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    9 December 2021
    View quality statements

    Sections for QS77